100th patient enrolled in US study ahead of schedule
Filed with ASX · · 3 pages · English
• Epiminder has enrolled the 100th participant in DETECT, its prospective, randomised, controlled, blinded, multi-centre US study of the Minder System, bringing the study to nearly half of its planned enrolment of up to 210 participants. • The milestone was achieved ahead of the Company’s November target, and reflects strong enrolment momentum across 22 world-class epilepsy centres in the United S
Earlier from Epiminder
- Updated Securities Trading Policy
- Change of Director's Interest Notice DO
- Notice of Annual General Meeting/Proxy Form
- 75th DETECT Enrollee
- Change of Director's Interest Notice PB
Later from Epiminder
- Quarterly Activities/Appendix 4C Cash Flow Report
- FY27 YTD operational update and AGM materials
- Minder System Cleared for Patients 12 -75 Years of Age
- Results of Annual General Meeting
- Change of Address
Follow Epiminder into a list and get an email when it puts out news.
Follow Epiminder